The store will not work correctly when cookies are disabled.
3-chloro-2,2-dimethyl-N-(3-((6-(methylamino)pyrimidin-4-yl)oxy)phenyl)propanamide
ID: ALA5291268
Max Phase: Preclinical
Molecular Formula: C16H19ClN4O2
Molecular Weight: 334.81
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: CNc1cc(Oc2cccc(NC(=O)C(C)(C)CCl)c2)ncn1
Standard InChI: InChI=1S/C16H19ClN4O2/c1-16(2,9-17)15(22)21-11-5-4-6-12(7-11)23-14-8-13(18-3)19-10-20-14/h4-8,10H,9H2,1-3H3,(H,21,22)(H,18,19,20)
Standard InChI Key: MCCRYXNDYLEZBK-UHFFFAOYSA-N
Molfile:
RDKit 2D
23 24 0 0 0 0 0 0 0 0999 V2000
4.2849 0.2206 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
3.5585 -0.1703 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8565 0.2632 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1301 -0.1277 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4282 0.3058 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.7018 -0.0851 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6772 -0.9098 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0492 -1.3008 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7510 -0.8672 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7264 -0.0425 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4283 0.3910 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.1547 0.0000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.8566 0.4336 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.5830 0.0426 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.2849 0.4762 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-4.2603 1.3008 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6077 -0.7820 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.9058 -1.2156 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.1793 -0.8246 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0000 0.3484 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1055 -0.9524 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.2730 0.8467 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2691 0.9779 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
3 2 1 0
4 3 1 0
4 5 1 0
6 5 1 0
6 7 1 0
8 7 2 0
9 8 1 0
10 9 2 0
11 10 1 0
12 11 1 0
12 13 1 0
13 14 2 0
15 14 1 0
16 15 1 0
17 14 1 0
17 18 2 0
18 19 1 0
19 12 2 0
20 10 1 0
6 20 2 0
4 21 2 0
3 22 1 0
3 23 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 334.81 | Molecular Weight (Monoisotopic): 334.1197 | AlogP: 3.51 | #Rotatable Bonds: 6 |
Polar Surface Area: 76.14 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 13.42 | CX Basic pKa: 4.78 | CX LogP: 3.32 | CX LogD: 3.32 |
Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.79 | Np Likeness Score: -1.48 |
References
1. Kim DR, Orr MJ, Kwong AJ, Deibler KK, Munshi HH, Bridges CS, Chen TJ, Zhang X, Lacorazza HD, Scheidt KA.. (2023) Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors., 14 (5): [PMID:37197477] [10.1021/acsmedchemlett.3c00029] |